September 8, 2021 -
In preparation for Peak Week, we welcome Dr. Mario Castro from University of Kansas School of Medicine to guide us through the myriad of emerging asthma biologic agents. While this novel drug class has heralded an era of targeted therapy, what are the promises and challenges? Dr. Castro discusses the inflammatory cascade that drives the disease process, along with the evolution of biomarkers used to predict treatment response.
Brought to you by the American Lung Association and HCPLive
Tune in and subscribe on:
Have an idea for a future Lungcast episode? Share your idea with us!
